{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Aliyu MH"],"funding":["NIDDK NIH HHS","National Institute of Diabetes and Digestive and Kidney Diseases"],"pagination":["341"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6558910"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["20(1)"],"pubmed_abstract":["<h4>Background</h4>Individuals with two copies of the apolipoprotein-1 (APOL1) gene risk variants are at high risk (HR) for non-diabetic kidney disease. The presence of these risk variants is highest in West Africa, specifically in Nigeria. However, there is limited availability of dialysis and kidney transplantation in Nigeria, and most individuals will die soon after developing end-stage renal disease. Blocking the renin angiotensin aldosterone system with angiotensin-converting enzyme inhibitors (ACEi) is a well-recognized strategy to slow renal disease progression in patients with diabetes mellitus with chronic kidney disease (CKD) and in patients with HIV-associated nephropathy. We propose to determine whether presence of the APOL1 HR genotype alters or predicts responsiveness to conv"],"journal":["Trials"],"pubmed_title":["Optimal management of HIV- positive adults at risk for kidney disease in Nigeria (Renal Risk Reduction \"R3\" Trial): protocol and study design."],"pmcid":["PMC6558910"],"funding_grant_id":["U01 DK12271","U01 DK112271"],"pubmed_authors":["Shepherd BE","Wester CW","Winkler CA","Kimmel PL","Ikizler TA","Abdu A","Muhammad H","Kopp JB","Gong W","Wudil UJ","Musa BM","Sani MU","Aliyu MH","Ingles DJ","Ahonkhai AA","Atanda A","Nalado AM"],"additional_accession":[]},"is_claimable":false,"name":"Optimal management of HIV- positive adults at risk for kidney disease in Nigeria (Renal Risk Reduction \"R3\" Trial): protocol and study design.","description":"<h4>Background</h4>Individuals with two copies of the apolipoprotein-1 (APOL1) gene risk variants are at high risk (HR) for non-diabetic kidney disease. The presence of these risk variants is highest in West Africa, specifically in Nigeria. However, there is limited availability of dialysis and kidney transplantation in Nigeria, and most individuals will die soon after developing end-stage renal disease. Blocking the renin angiotensin aldosterone system with angiotensin-converting enzyme inhibitors (ACEi) is a well-recognized strategy to slow renal disease progression in patients with diabetes mellitus with chronic kidney disease (CKD) and in patients with HIV-associated nephropathy. We propose to determine whether presence of the APOL1 HR genotype alters or predicts responsiveness to conv","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 Jun","modification":"2026-05-07T01:12:51.01Z","creation":"2019-07-24T07:14:32Z"},"accession":"S-EPMC6558910","cross_references":{"pubmed":["31182139"],"doi":["10.1186/s13063-019-3436-y"]}}